IgA-话题@MedSci

#IgA#

129篇内容 | 3264人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1503967, encodeId=da3a150396eef, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度, objectType=article, longId=211226, objectId=31d02112268e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d02112268e, replyNumber=0, likeNumber=67, createdTime=2021-05-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d02112268e, moduleTitle=Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31d02112268e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503966, encodeId=7a57150396665, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, objectType=article, longId=210971, objectId=aae42109e1a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae42109e1a9, replyNumber=0, likeNumber=69, createdTime=2021-05-10, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae42109e1a9, moduleTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae42109e1a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503965, encodeId=9827150396564, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=J Allergy Clin Immunol：猫尾草皮下和舌下免疫疗法对过敏原特异性IgA反应的不同诱导作用, objectType=article, longId=210436, objectId=56fe21043635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56fe21043635, replyNumber=0, likeNumber=0, createdTime=2021-04-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56fe21043635, moduleTitle=J Allergy Clin Immunol：猫尾草皮下和舌下免疫疗法对过敏原特异性IgA反应的不同诱导作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56fe21043635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503964, encodeId=27791503964ad, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”, objectType=article, longId=207390, objectId=460c20e390d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460c20e390d3, replyNumber=0, likeNumber=82, createdTime=2021-02-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460c20e390d3, moduleTitle=Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460c20e390d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503963, encodeId=e4a715039635f, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=JAHA：Sirtuin 3通过调节TIGAR和心肌细胞代谢缓解糖尿病心肌病, objectType=article, longId=207214, objectId=dd8520e21456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8520e21456, replyNumber=0, likeNumber=79, createdTime=2021-02-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8520e21456, moduleTitle=JAHA：Sirtuin 3通过调节TIGAR和心肌细胞代谢缓解糖尿病心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8520e21456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503962, encodeId=3ab615039625f, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=59, createdTime=2021-02-11, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503961, encodeId=25ce150396156, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, objectType=article, longId=206525, objectId=468b20652504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468b20652504, replyNumber=0, likeNumber=69, createdTime=2021-02-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468b20652504, moduleTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468b20652504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Nat Commun：NOD2的缺乏促进克罗恩病分泌型IgA复合物的逆向转运, objectType=article, longId=205966, objectId=e96420596634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e96420596634, replyNumber=0, likeNumber=101, createdTime=2021-01-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e96420596634, moduleTitle=Nat Commun：NOD2的缺乏促进克罗恩病分泌型IgA复合物的逆向转运, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e96420596634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503959, encodeId=2713150395905, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Laboratory Investigation：GTSE1通过SP1/FOXM1信号通路促进前列腺癌细胞增殖, objectType=article, longId=205416, objectId=435d20541691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435d20541691, replyNumber=0, likeNumber=0, createdTime=2021-01-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435d20541691, moduleTitle=Laboratory Investigation：GTSE1通过SP1/FOXM1信号通路促进前列腺癌细胞增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435d20541691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503958, encodeId=b80b15039585d, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Clinica Chimica Acta： IgA在SARS-CoV-2感染早期的作用？, objectType=article, longId=205285, objectId=a558205285e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a558205285e4, replyNumber=0, likeNumber=63, createdTime=2021-01-05, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a558205285e4, moduleTitle=Clinica Chimica Acta： IgA在SARS-CoV-2感染早期的作用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a558205285e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503957, encodeId=308e150395ea0, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, objectType=article, longId=204053, objectId=0bbe204053d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbe204053d5, replyNumber=0, likeNumber=87, createdTime=2020-12-04, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbe204053d5, moduleTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbe204053d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503956, encodeId=46441503956ae, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=口服类固醇Nefecon治疗原发性IgA肾病，达到III期关键临床终点, objectType=article, longId=203211, objectId=9a9e20321106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9e20321106, replyNumber=0, likeNumber=76, createdTime=2020-11-11, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9e20321106, moduleTitle=口服类固醇Nefecon治疗原发性IgA肾病，达到III期关键临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9e20321106)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=NEJM：万古霉素诱导的线性IgA大疱性皮肤病-病例报道, objectType=article, longId=202126, objectId=b04120212689, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b04120212689, replyNumber=0, likeNumber=91, createdTime=2020-10-16, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b04120212689, moduleTitle=NEJM：万古霉素诱导的线性IgA大疱性皮肤病-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b04120212689)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503954, encodeId=8dfb15039544d, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％, objectType=article, longId=200077, objectId=0d5f2000e754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d5f2000e754, replyNumber=0, likeNumber=60, createdTime=2020-09-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d5f2000e754, moduleTitle=Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d5f2000e754)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503953, encodeId=7807150395368, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=临床干货：IgA肾病怎样使用激素？, objectType=article, longId=198112, objectId=a419198112bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a419198112bf, replyNumber=0, likeNumber=0, createdTime=2020-07-28, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a419198112bf, moduleTitle=临床干货：IgA肾病怎样使用激素？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a419198112bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503952, encodeId=437d15039527b, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=49, createdTime=2020-07-20, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503951, encodeId=094415039517d, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=达格列净（Forxiga）在印度获准用于治疗射血分数降低的心衰患者, objectType=article, longId=197127, objectId=959b19e127a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=959b19e127a8, replyNumber=0, likeNumber=83, createdTime=2020-07-08, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=959b19e127a8, moduleTitle=达格列净（Forxiga）在印度获准用于治疗射血分数降低的心衰患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=959b19e127a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503950, encodeId=68fb150395031, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=75, createdTime=2020-06-17, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503949, encodeId=f5b2150394951, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=Cell Mol Immunol：新冠病毒感染后出现IgA、IgM和IgG三种抗体应答时空特征, objectType=article, longId=195671, objectId=a3281956e18d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3281956e18d, replyNumber=0, likeNumber=57, createdTime=2020-06-12, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3281956e18d, moduleTitle=Cell Mol Immunol：新冠病毒感染后出现IgA、IgM和IgG三种抗体应答时空特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3281956e18d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1503948, encodeId=2a97150394839, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, objectTitle=NEJM：线性IgA大疱性皮肤病-病例报道, objectType=article, longId=195296, objectId=03e4195296fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03e4195296fb, replyNumber=0, likeNumber=61, createdTime=2020-06-06, rootId=0, userName=yibei, userId=c23f9697922, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03e4195296fb, moduleTitle=NEJM：线性IgA大疱性皮肤病-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03e4195296fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IgA

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度

2021-05-14

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点

2021-05-10

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

J Allergy Clin Immunol：猫尾草皮下和舌下免疫疗法对过敏原特异性IgA反应的不同诱导作用

2021-04-26

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

Sparsentan治疗IgA肾病（IgAN），EMA已授予Sparsentan“孤儿药称号”

2021-02-22

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

JAHA：Sirtuin 3通过调节TIGAR和心肌细胞代谢缓解糖尿病心肌病

2021-02-18

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-02-11

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价

2021-02-02

智者为医08 (审核中...)

前往app查看评论内容

#IgA#

Nat Commun：NOD2的缺乏促进克罗恩病分泌型IgA复合物的逆向转运

2021-01-22

yibei (审核中...)

前往app查看评论内容

#IgA#

Laboratory Investigation：GTSE1通过SP1/FOXM1信号通路促进前列腺癌细胞增殖

2021-01-08

yibei (审核中...)

前往app查看评论内容

#IgA#

Clinica Chimica Acta： IgA在SARS-CoV-2感染早期的作用？

2021-01-05

yibei (审核中...)

前往app查看评论内容

#IgA#

FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期

2020-12-04

yibei (审核中...)

前往app查看评论内容

#IgA#

口服类固醇Nefecon治疗原发性IgA肾病，达到III期关键临床终点

2020-11-11

yibei (审核中...)

前往app查看评论内容

#IgA#

NEJM：万古霉素诱导的线性IgA大疱性皮肤病-病例报道

2020-10-16

仁医06 (审核中...)

前往app查看评论内容

#IgA#

Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％

2020-09-02

yibei (审核中...)

前往app查看评论内容

#IgA#

临床干货：IgA肾病怎样使用激素？

2020-07-28

yibei (审核中...)

前往app查看评论内容

#IgA#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-07-20

yibei (审核中...)

前往app查看评论内容

#IgA#

达格列净（Forxiga）在印度获准用于治疗射血分数降低的心衰患者

2020-07-08

yibei (审核中...)

前往app查看评论内容

#IgA#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-06-17

yibei (审核中...)

前往app查看评论内容

#IgA#

Cell Mol Immunol：新冠病毒感染后出现IgA、IgM和IgG三种抗体应答时空特征

2020-06-12

yibei (审核中...)

前往app查看评论内容

#IgA#

NEJM：线性IgA大疱性皮肤病-病例报道

2020-06-06

科室
- - 订阅+
  - 更多科室
工具
服务